← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Goserelin

FDA approved · Rx

GnRH agonist peptide

Also known as: Zoladex, Decapeptide I, Goserelina, Gosereline, Goserelinum, ICI-118630, ICI 118630, ICI 118,630

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 417 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Goserelin is a synthetic peptide analog of gonadotropin-releasing hormone (GnRH), sold under the brand name Zoladex. After an initial surge, continued exposure desensitizes GnRH receptors in the pituitary, which lowers production of LH and FSH and in turn reduces testosterone and estrogen levels.

What the evidence shows

Automatic summaryHuman trials

Goserelin is FDA-approved as a prescription drug, approved for conditions including advanced prostate cancer, certain breast cancers, endometriosis, and endometrial thinning before surgery. It has a large body of human evidence, with over 400 registered trials reaching Phase 4 and more than 1,200 published papers.

Key facts

Molecular formula
C59H84N18O14
Molecular weight
1269.4 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

417registered studies
Phase 4most advanced phase
42completed (sample)
13recruiting (sample)

A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer

Phase 2CompletedNCT00108732

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Phase 2Active Not RecruitingNCT01723774

Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate

Phase 2UnknownNCT04736108

Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)

Phase 2RecruitingNCT07313241

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

1,264papers referencing Goserelin

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

N Engl J Med2015

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Lancet2002

Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

N Engl J Med1997

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.

N Engl J Med1999

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.